A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

Completed

• Conditions: Multiple Sclerosis

• Registration Number: NCT00238654
• Lead Sponsor: Teva Neuroscience, Inc.

Brief Summary

This study has patients responding to two sets of surveys that will tell their doctor or nurse about their readiness to begin self-injection. In addition, patients will have their self-injection observed and evaluated on up to three visits

Detailed Description

Not available

Study Timeline

• Study Start: 2003-05
• Study First Submitted: 2005-10-12
• Study First Submitted QC: 2005-10-12
• Study First Posted: 2005-10-13
• Primary Completion: 2008-07
• Study Completion: 2008-07
• Status Verified: 2011-04
• Last Update Submitted: 2011-04-08
• Last Update Posted: 2011-04-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 257

Inclusion Criteria

1. Male or Female, 18 years of age or older, with diagnosis of RRMS
2. Naive to treatment or previously treated with an IFN.

Exclusion Criteria

1. Not eligible for treatment based on clinical criteria and current indication.
2. Unable to respond to surveys or provide informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adherence of self-injection assessed by self-report at each follow-up visit	12 months